Sunir Joshi is an Ophthalmology physician. OpenAlex indexes 12 publications with 641 citations (h-index 5).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
6000 Hillandale Dr Ste 130
Lithonia, GA 300584860
Telephone
678-892-2020Provider last certified this registry record 27 May 2026.
Industry payments
20 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Regeneron Pharmaceuticals, Inc.Program year202515 payments
- Genentech USA, Inc.Program year20257 payments
- ABBVIE INC.Program year20259 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
95.9%Antineovascularisation agents75.5%Faricimab-svoa100%Part B, office-administered≥14 patientsProstaglandin Analog10.9%Latanoprost83%Lumigan17%Part D≥50 patients+ 5 more classes in this area
Cancer & immunology
3.1%Vascular Endothelial Growth Factor Inhibitor2.4%Bevacizumab100%Part B, office-administered≥23 patientsCalcineurin inhibitor0.7%Restasis100%Part D<11 patientsCardiovascular
1%Beta blocker1%Timolol Maleate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Plain language summary of publication of the 96-week results from the PHOTON study: intravitreal aflibercept 8 mg for diabetic macular edema
Therapeutic Advances in Ophthalmology
2026 - Intravitreal aflibercept 8 mg in patients from Japan with diabetic macular edema: 48-week subgroup analysis of the PHOTON trial
Japanese Journal of Ophthalmology
2025 - Plain language summary of publication of the 48-week results from the PHOTON study: intravitreal aflibercept 8 mg for diabetic macular edema
Therapeutic Advances in Ophthalmology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Ali Bijani
Babol University of Medical Sciences
Hamid Asayesh
Ayatollah Boroujerdi University
John J. Huang
Isfahan University of Medical Sciences
Fotis Topouzis
National University of Singapore
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”